Retatrutide (GLP-3) Dosing Guide: 2mg to 12mg Protocol

Retatrutide Dosing Schedule Overview

Retatrutide (reta) is a triple agonist targeting GLP-1, GIP, and glucagon receptors. Phase 2 trials showed up to 24.2% weight loss at 48 weeks, more than any other GLP-1 class medication tested so far. The dosing protocol matters because titrating too fast is the main cause of intolerable side effects.

The standard retatrutide dosing protocol follows a gradual titration approach, similar to other GLP-1 agonists like semaglutide and tirzepatide. This slow increase allows your body to adapt to the medication and helps manage common gastrointestinal side effects.

Use our free retatrutide dosing calculator to visualize your specific protocol and see projected drug levels over time.

Understanding Retatrutide: Mechanism and Pharmacology

What it is: Retatrutide (LY3437943) is an injectable that activates three metabolic receptors: GLP-1, GIP, and glucagon. Semaglutide targets only GLP-1; tirzepatide targets GLP-1 and GIP. The added glucagon receptor activation increases energy expenditure and fat burning.

Triple-Agonist Mechanism of Action

The net result: reduced appetite (GLP-1), improved insulin action and fat metabolism (GIP), plus increased energy expenditure (glucagon). Phase 2 data showed up to 24.2% weight loss at 48 weeks with the 12mg dose. Each additional receptor target has produced incrementally better outcomes in clinical trials.

Starting Dose for Retatrutide

The recommended retatrutide starting dose is 2mg once weekly. This dose won't produce significant weight loss on its own. It's there to let your body adjust before moving to therapeutic doses.

Why Start at 2mg?

• GI adaptation: Lower doses allow the digestive system to adjust, reducing nausea and vomiting
• Triple receptor activation: Retatrutide's unique GLP-1/GIP/glucagon mechanism requires gradual introduction
• Safety monitoring: Assess individual response before increasing to therapeutic doses
• Injection site tolerance: Verify no local reactions before committing to higher doses

What to Expect in the First Week

During the initial retatrutide dose, you may experience:

• Mild appetite reduction (typically noticeable by days 2-3)
• Possible nausea, especially with large or fatty meals
• Minor injection site reaction (redness, mild swelling)
• Increased satiety after smaller portions

Retatrutide Titration Schedule

The retatrutide titration schedule follows a 4-week escalation pattern. For a quick visual reference, download our printable retatrutide dosage chart. Each dose increase should only occur if the current dose is well-tolerated.

Week-by-Week Breakdown

For the complete titration schedule with detailed timing, see our full retatrutide protocol.

When to Delay Dose Escalation

Hold your current retatrutide dose and don't escalate if you experience:

• Persistent nausea or vomiting (more than 3 days after injection)
• Severe constipation or diarrhea
• Significant injection site reactions
• Rapid weight loss (more than 3-4 lbs/week consistently)
• Signs of dehydration from GI symptoms

It's acceptable to remain at a dose longer than 4 weeks if needed. Some users stay at 4mg or 8mg for 6-8 weeks before escalating. The titration schedule is a guideline, not a requirement.

Conservative Titration (Community Approach)

Some community members prefer an even more gradual approach, starting at 1mg weekly before moving to the trial-based 2mg starting dose. This can be helpful for:

• Individuals with a history of GI sensitivity
• Those who experienced significant side effects with other GLP-1 medications
• People who prefer the most cautious approach possible

Microdosing Retatrutide: Alternative Approach

Some users explore microdosing retatrutide, splitting the weekly dose into multiple smaller injections. This approach aims to reduce side effects by maintaining more stable drug levels.

Common Microdosing Protocols

Read our microdosing retatrutide guide for detailed protocols, benefits, risks, and pharmacokinetic modeling.

Retatrutide Half-Life and Steady State

Understanding retatrutide's pharmacokinetics helps explain why the dosing schedule is structured as it is.

Half-Life: ~6 Days

Retatrutide has a terminal half-life of approximately 6 days, meaning half of the drug is eliminated from your body every 6 days. This extended half-life allows for once-weekly dosing and explains why effects persist even if you miss a dose.

Half-life, in plain language: If you inject 5 mg on day 0, about 2.5 mg remains ~6 days later, and ~1.25 mg after ~12 days. Because levels fall slowly, once-weekly dosing works well.

Trial data comparison shows the progression from single-agonist (semaglutide) to dual-agonist (tirzepatide) to triple-agonist (retatrutide) correlates with increasing weight loss efficacy. Note that trial durations differ and head-to-head comparisons are not yet available.

Illustrative side-effect timeline (not trial data). Half-lives for reference: retatrutide ~6 days, tirzepatide ~5 days, semaglutide ~7 days.

Steady State: 4-5 Weeks

Why steady state matters: Most drugs reach steady state after ~4–5 half-lives, which for retatrutide is about 4–5 weeks of weekly injections. That's when peaks and troughs stop rising and therapeutic effects become consistent. Understanding this pharmacokinetic principle helps set realistic expectations for symptom improvement.

Weekly vs microdosing: Note the smoother levels with split dosing (lower peaks, higher troughs)

Our retatrutide calculator can model your specific protocol and show when you'll reach steady state at each dose level.

Using a Retatrutide Dosing Calculator

A dosing calculator helps you visualize how retatrutide builds up in your system over time and what to expect at different doses and frequencies.

What GLP3 Planner Can Help You Understand

• Drug concentration curves: See how levels rise and fall between injections
• Steady state timing: Know when to expect stable drug levels
• Dose comparison: Compare different titration schedules side-by-side
• Microdosing modeling: Visualize split-dose protocols
• Shareable schedules: Create URLs to discuss your protocol with providers

Retatrutide vs Other GLP-1 Dosing

How does retatrutide dosing compare to other popular GLP-1 agonists? Here's a quick comparison:

While dosing schedules appear similar, retatrutide's triple-receptor mechanism (GLP-1 + GIP + glucagon) produces different effects than dual-agonists like tirzepatide or single-agonists like semaglutide.

Looking for alternatives? See our comparison guides:

• GLP-1 Plotter Alternatives - Compare free dose calculators
• Shotsy Alternatives - Free tracking app options
• Glapp Alternatives - GLP-1 app comparison

Retatrutide Clinical Trial Data and Efficacy

Retatrutide dosing protocols are based on clinical trial data from Eli Lilly's development program. Here's what the trials have shown:

Phase 1b Trial Results (Lancet 2022)

The initial Phase 1b study evaluated retatrutide safety, tolerability, and pharmacokinetics in 72 adults with type 2 diabetes over 12 weeks. Participants received multiple ascending once-weekly doses in cohorts of 0.5, 1.5, 3, 3/6 and 3/6/9/12 mg. Placebo-adjusted weight change reached -8.96 kg in the 3/6/9/12 mg group. Treatment-emergent adverse events of any kind occurred in 63% of participants on retatrutide, 60% on dulaglutide 1.5 mg and 54% on placebo, and gastrointestinal disorders were the most frequent. The study established the ~6-day half-life and confirmed once-weekly dosing feasibility.

Phase 2 Trial Results (NEJM 2023)

The landmark Phase 2 trial enrolled 338 adults with obesity (BMI ≥30) or overweight with comorbidities (BMI ≥27) but without diabetes. Participants were randomized to placebo or retatrutide at 1 mg, 4 mg (dose-escalation), 4 mg (no escalation), 8 mg (escalation), 8 mg (no escalation), or 12 mg (escalation) for 48 weeks, following a slow titration protocol.

Safety profile: The most common adverse events were gastrointestinal; they were dose-related, mostly mild to moderate, and partially mitigated with a lower starting dose (2 mg vs. 4 mg). In the trial's posted results on ClinicalTrials.gov (NCT04881760), the 12 mg group reported nausea in 45%, decreased appetite in 29%, vomiting in 19%, constipation in 16% and diarrhea in 15%, versus 11%, 9%, 1%, 3% and 11% on placebo. Starting dose mattered: at 8 mg, nausea affected 17% of people who started at 2 mg and 60% of those who started at 4 mg. Dose-dependent increases in heart rate peaked at 24 weeks and declined thereafter.

Metabolic Improvements Beyond Weight

Secondary outcomes showed improvements in cardiometabolic markers. At 48 weeks with the 12mg dose: systolic blood pressure dropped 7.4 mmHg, triglycerides fell 30%, HDL cholesterol increased 8%, and HbA1c decreased 0.4% even in participants without diabetes. The metabolic improvements track with what you'd expect from this level of weight loss, though the glucagon component may contribute independently to some of these effects.

Phase 3 results have now been reported: TRIUMPH-4 in December 2025, then TRIUMPH-1 in the New England Journal of Medicine and TRIUMPH-2 in The Lancet, both in September 2026. Further TRIUMPH trials, including TRIUMPH-5 versus tirzepatide, are ongoing. View trials on ClinicalTrials.gov →

Common Side Effects & Management Strategies

GI symptoms are the most frequent and tend to appear during the first weeks or after dose increases. In trials, GI events were dose-related and were partially mitigated with a lower starting dose. The figures below are trial data, not label rates (retatrutide has no FDA label): the Phase 2 trial's posted results (12 mg vs placebo, 48 weeks) and Phase 3 TRIUMPH-1 (Jastreboff et al., NEJM 2026; 4 to 12 mg vs placebo, adults with obesity or overweight without diabetes, 80 weeks). These are separate trials with different populations and durations.

Most Common Side Effects

Other Common Effects

• Abdominal discomfort / reflux: Often linked to meal size or timing. Eat smaller meals; don't lie down after eating.
• Headache: Sometimes from dehydration or low intake. Stay hydrated; ensure electrolytes.
• Fatigue: Common as intake drops. Ensure adequate sleep and protein at meals.
• Resting heart-rate increase: In Phase 2, dose-dependent increases in heart rate peaked at 24 weeks and declined thereafter. Stay hydrated; limit stimulants; monitor; report palpitations.
• Injection-site reactions: Mild redness/itching/lumps. Rotate sites; use proper technique; cool compress if needed.

Clinical Scenarios for Dosing Schedule Optimization

• Evaluating microdosing protocols: Assess how split dosing affects peak-to-trough variation compared to standard weekly administration. Read about microdosing pharmacokinetics.
• Managing missed doses: Understand drug level depletion when doses are skipped and plan resumption timing. Consult with your healthcare provider about make-up dose strategies.
• Dose escalation planning: Anticipate steady-state changes when transitioning to higher maintenance doses during titration.
• Minimizing concentration-dependent adverse events: Evaluate whether dose-splitting might reduce peak-related gastrointestinal symptoms based on pharmacokinetic modeling.
• Schedule flexibility: Understand how injection timing shifts affect plasma concentrations for travel or lifestyle adjustments.